Therapeutic approaches that inhibit specific mediators, first demonstrated with selumetinib, a MAPK pathway inhibitor, and subsequently with BRAF mutation inhibitors, have demonstrated the ability to restore RAI uptake for patients with metastatic RAI-refractory thyroid cancer (6, 7). This evidence concerns the gene BRAF and thyroid gland carcinoma.